Han Liu

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 11

Top Venues

Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

Shanghai Jiao Tong University School of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

China

Professor/PI :: Shanghai Institute of Hematology

Memorial Sloan Kettering Cancer Center

United States

Senior Research Scientist :: HOPP

Washington University in Saint Louis School of Medicine

United States

Postdoctoral Scholar/Research Instructor :: Oncology

Education History

Shanghai Jiao Tong University School of Medicine

China

PHD

Peking University

China

MSC

Peking University

China

BSC

Publications

Shufeng Xie, Hui Liu, Shouhai Zhu, Zhihong Chen, Ruiheng Wang, Wenjie Zhang, Huajian Xian, Rufang Xiang, Xiaoli Xia, Yong Sun, Jinlan Long, Yuanli Wang, Minghui Wang, Yixin Wang, Yaoyifu Yu, Zixuan Huang, Chaoqun Lu, Zhen-Shu Xu, Han Liu
Arsenic trioxide and p97 inhibitor synergize against acute myeloid leukemia by targeting nascent polypeptides and activating the ZAKα-JNK pathway. Cancer gene therapy (2024)
Yong Sun, Ruiheng Wang, Shufeng Xie, Yuanli Wang, Han Liu
A Novel Identified Necroptosis-Related Risk Signature for Prognosis Prediction and Immune Infiltration Indication in Acute Myeloid Leukemia Patients. Genes 13 (10) (2022)
Ruiheng Wang, Shufeng Xie, Shouhai Zhu, Yong Sun, Bowen Shi, Dan Li, Ting Kang, Yuanli Wang, Zhen-Shu Xu, Han Liu
Targeting matrix metallopeptidase 2 by hydroxyurea selectively kills acute myeloid mixed-lineage leukemia. Cell death discovery 8 (1) (2022)
Maolin Ge, Qiongyu Xu, Ting Kang, Dan Li, Ruiheng Wang, Zhihong Chen, Shufeng Xie, Wenbin Wang, Han Liu
Deubiquitinating enzyme inhibitor alleviates cyclin A1-mediated proteasome inhibitor tolerance in mixed-lineage leukemia. Cancer science 112 (6) (2021)
Shouhai Zhu, Xiaoyan Cheng, Ruiheng Wang, Yuting Tan, Maolin Ge, Dan Li, Qiongyu Xu, Yan Sun, Chunjun Zhao, Saijuan Chen, Han Liu
Restoration of microRNA function impairs MYC-dependent maintenance of MLL leukemia. Leukemia 34 (9) (2020)
Maolin Ge, Zhi Qiao, Yan Kong, Hongyu Liang, Yan Sun, Hui Lu, Zhen-Shu Xu, Han Liu
Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance. British journal of cancer 124 (4) (2020)
Maolin Ge, Zhi Qiao, Yan Kong, Hui Lu, Han Liu
Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia. Cancer science 111 (4) (2020)
Maolin Ge, Dan Li, Zhi Qiao, Yan Sun, Ting Kang, Shouhai Zhu, Shifen Wang, Hua Xiao, Chunjun Zhao, Shuhong Shen, Zhen-Shu Xu, Han Liu
Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors. Oncogene 39 (36) (2020)
Xiaoyan Cheng, Maolin Ge, Shouhai Zhu, Dan Li, Ruiheng Wang, Qiongyu Xu, Zhihong Chen, Shufeng Xie, Han Liu
mTORC1-mediated amino acid signaling is critical for cell fate determination under transplant-induced stress. FEBS letters 595 (4) (2020)
Shouhai Zhu, Zhihong Chen, Ruiheng Wang, Yuting Tan, Maolin Ge, Yan Sun, Dan Li, Yutian Hu, Chunjun Zhao, Zhu Chen, Saijuan Chen, Han Liu
MLL is required for miRNA-mediated translational repression. Cell discovery 5 (2019)
Shifen Wang, Maolin Ge, Jing Cui, Zhi Qiao, Xiuli Chen, Shunquan Wu, Rong Zhan, Huarong Zhou, Han Liu, Zhenshu Xu
Diminished interaction between mutant NOTCH1 and the NuRD corepressor complex upregulates CCL17 in chronic lymphocytic leukemia. Leukemia 33 (12) (2019)

Han Liu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Han Liu